Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
Multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe COVID-19 infection receiving/not treatment with antithrombin (AT) III
Description: Levels of AT in severely ill COVID-19 positive patients receiving/not receiving ATIII treatment
Measure: Antithrombin Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: aPPT Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: aPPT Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: PT Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: PT Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: Quick Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: Quick Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: INR Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: INR Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: D-dimer Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: D-dimer Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: Fibrinogen Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: Fibrinogen Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: Haemoglobin Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: Haemoglobin Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: Platelet Levels in severely ill COVID-19 patients receiving/not receiving ATIII treatment and compared to control group
Measure: Platelet Levels Time: throughout hospitalization, approximately 1-3 weeksDescription: Comparison of the occurrence of thromboembolic complications and bleeding events between groups
Measure: Thromboembolic complications and bleeding events between groups Time: throughout hospitalization, approximately 1-3 weeksDescription: Comparison of the duration of requirement for oxygen therapy, and invasive ventilation support or ECMO between groups
Measure: Comparison of the duration of requirement for oxygen therapy, and invasive ventilation support or ECMO between groups Time: throughout hospitalization, approximately 1-3 weeksDescription: Hospital length of stay between groups
Measure: Hospital length of stay Time: throughout hospitalization, approximately 1-3 weeksDescription: Number of days in ICU between groups
Measure: Number of days in ICU Time: throughout hospitalization, approximately 1-3 weeksDescription: Number of days requiring oxygenation between groups
Measure: Number of days requiring oxygenation Time: throughout hospitalization, approximately 1-3 weeksDescription: Discharge disposition between groups
Measure: Discharge disposition Time: throughout hospitalization, approximately 1-3 weeksDescription: Mortality between groups
Measure: Mortality Time: throughout hospitalization, approximately 1-3 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports